BBruno Sarmento is Principal Investigator and Group Leader at Institute for Research and Innovation in Health (i3S), University of Porto (UP), and Invited Associate Professor at Instituto Universitário de Ciências da Saúde (IUCS), Portugal. His research is focused on the development of mucosal tissue engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlation. He has also established functionalized nanomedicines for mucosal drug delivery of drug with poor mucosal bioavailability. He published more than 400 papers in international journals, most in top journals (20000 Scopus citations; H-index 73). He edited 5 books, participated in more than 50 invited/selected talks in national and international meetings and was awarded several distinctions. He has supervised/co-supervised 15 Post-Docs, 50 PhD students and 40 MSc students. He is editor of European Journal of Pharmaceutical Sciences, and member of the Editorial Advisory Board of several international journals, including the Journal of Controlled Release, Expert Opinion on Drug Delivery and Pharmaceutics. Bruno Sarmento was the first Chair of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society (CRS) and is now Director-at-Large of CRS and member of CRS College of Fellows.

Select Guide Rating

• 1. Introduction2. Importance and applications of cell and tissue-based in vitro models for drug permeability screening in early stages of drug development3. Immortalized cell-based in vitro culture models for drug permeability studies4. Primary isolated cell-based in vitro culture models for drug permeability studies5. Tissue-based in vitro culture models for drug permeability studies6. Correlation between cell and tissue-based in vitro models for drug permeability screening with in vivo situation: Modeling and functional extrapolation

BBruno Sarmento is Principal Investigator and Group Leader at Institute for Research and Innovation in Health (i3S), University of Porto (UP), and Invited Associate Professor at Instituto Universitário de Ciências da Saúde (IUCS), Portugal. His research is focused on the development of mucosal tissue engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlation. He has also established functionalized nanomedicines for mucosal drug delivery of drug with poor mucosal bioavailability. He published more than 400 papers in international journals, most in top journals (20000 Scopus citations; H-index 73). He edited 5 books, participated in more than 50 invited/selected talks in national and international meetings and was awarded several distinctions. He has supervised/co-supervised 15 Post-Docs, 50 PhD students and 40 MSc students. He is editor of European Journal of Pharmaceutical Sciences, and member of the Editorial Advisory Board of several international journals, including the Journal of Controlled Release, Expert Opinion on Drug Delivery and Pharmaceutics. Bruno Sarmento was the first Chair of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society (CRS) and is now Director-at-Large of CRS and member of CRS College of Fellows.

Select Guide Rating

• 1. Introduction2. Importance and applications of cell and tissue-based in vitro models for drug permeability screening in early stages of drug development3. Immortalized cell-based in vitro culture models for drug permeability studies4. Primary isolated cell-based in vitro culture models for drug permeability studies5. Tissue-based in vitro culture models for drug permeability studies6. Correlation between cell and tissue-based in vitro models for drug permeability screening with in vivo situation: Modeling and functional extrapolation

BBruno Sarmento is Principal Investigator and Group Leader at Institute for Research and Innovation in Health (i3S), University of Porto (UP), and Invited Associate Professor at Instituto Universitário de Ciências da Saúde (IUCS), Portugal. His research is focused on the development of mucosal tissue engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlation. He has also established functionalized nanomedicines for mucosal drug delivery of drug with poor mucosal bioavailability. He published more than 400 papers in international journals, most in top journals (20000 Scopus citations; H-index 73). He edited 5 books, participated in more than 50 invited/selected talks in national and international meetings and was awarded several distinctions. He has supervised/co-supervised 15 Post-Docs, 50 PhD students and 40 MSc students. He is editor of European Journal of Pharmaceutical Sciences, and member of the Editorial Advisory Board of several international journals, including the Journal of Controlled Release, Expert Opinion on Drug Delivery and Pharmaceutics. Bruno Sarmento was the first Chair of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society (CRS) and is now Director-at-Large of CRS and member of CRS College of Fellows.

Select Guide Rating

• 1. Introduction2. Importance and applications of cell and tissue-based in vitro models for drug permeability screening in early stages of drug development3. Immortalized cell-based in vitro culture models for drug permeability studies4. Primary isolated cell-based in vitro culture models for drug permeability studies5. Tissue-based in vitro culture models for drug permeability studies6. Correlation between cell and tissue-based in vitro models for drug permeability screening with in vivo situation: Modeling and functional extrapolation